Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Head and Neck Cancer

  Free Subscription


Articles published in J Clin Endocrinol Metab

Retrieve available abstracts of 199 articles:
HTML format



Single Articles


    August 2021
  1. GIOVANELLA L, Garo ML, Ceriani L, Paone G, et al
    Procalcitonin as an alternative tumor marker of medullary thyroid carcinoma. A meta-analysis.
    J Clin Endocrinol Metab. 2021 Aug 12. pii: 6348893. doi: 10.1210.
    PubMed     Abstract available


    July 2021
  2. IESATO A, Li S, Roti G, Hacker MR, et al
    Lenvatinib targets PDGFR-beta pericytes and inhibits synergy with thyroid carcinoma cells: novel translational insights.
    J Clin Endocrinol Metab. 2021 Jul 24. pii: 6327813. doi: 10.1210.
    PubMed     Abstract available


    June 2021
  3. PAULSSON JO, Rafati N, DiLorenzo S, Chen Y, et al
    Whole-genome sequencing of follicular thyroid carcinomas reveal recurrent mutations in microRNA processing subunit DGCR8.
    J Clin Endocrinol Metab. 2021 Jun 25. pii: 6309631. doi: 10.1210.
    PubMed     Abstract available


  4. HENDERSON YC, Mohamed ASR, Maniakas A, Chen Y, et al
    A High-Throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2021 Jun 12. pii: 6297567. doi: 10.1210.
    PubMed     Abstract available


    May 2021
  5. RAUE F, Bruckner T, Frank-Raue K
    Similar stage-dependent survival and outcome in sporadic and hereditary medullary thyroid carcinoma.
    J Clin Endocrinol Metab. 2021 May 11. pii: 6273583. doi: 10.1210.
    PubMed     Abstract available


    March 2021
  6. MALCHOFF CD
    Inherited Risk Factors for Nonmedullary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2021 Mar 19. pii: 6178882. doi: 10.1210.
    PubMed    



  7. Corrigendum to: "Efficacy and Safety of Thermal Ablation for Solitary T1bN0M0 Papillary Thyroid Carcinoma: A Multicenter Study".
    J Clin Endocrinol Metab. 2021 Mar 17. pii: 6174651. doi: 10.1210.
    PubMed    


    February 2021
  8. ZAYED AA, Amarin JZ, Al-Ani AT, Altell TL, et al
    Association of parental consanguinity with papillary thyroid carcinoma: a case-control study.
    J Clin Endocrinol Metab. 2021 Feb 15. pii: 6135109. doi: 10.1210.
    PubMed     Abstract available


    January 2021
  9. WAN D, Yang X, Li G, Du Y, et al
    A Set of Markers Related to Viral-Infection Has a Sex-sensitive Prognostic Value in Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2021 Jan 4. pii: 6062460. doi: 10.1210.
    PubMed     Abstract available


  10. ZHANG H, Zhang Z, Liu X, Duan H, et al
    DNA methylation haplotype block markers efficiently discriminate follicular thyroid carcinoma from follicular adenoma.
    J Clin Endocrinol Metab. 2021 Jan 4. pii: 6062414. doi: 10.1210.
    PubMed     Abstract available


  11. MURPHY CF, Stratford N, Docherty NG, Moran B, et al
    A Pilot Study of Gut-Brain Signaling After Octreotide Therapy for Unintentional Weight Loss After Esophagectomy.
    J Clin Endocrinol Metab. 2021;106:e204-e216.
    PubMed     Abstract available


    December 2020
  12. LIU Y, Wu S, Zhou L, Guo Y, et al
    Pitfalls in RET fusion detection using break-apart FISH probes in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2020 Dec 31. pii: 6056485. doi: 10.1210.
    PubMed     Abstract available


  13. NIES M, Vassilopoulou-Sellin R, Bassett RL, Yedururi S, et al
    Distant metastases from childhood differentiated thyroid carcinoma: clinical course and mutational landscape.
    J Clin Endocrinol Metab. 2020 Dec 31. pii: 6056477. doi: 10.1210.
    PubMed     Abstract available


  14. DAMJANOVIC SS, Antic JA, Elezovic-Kovacevic VI, Dundjerovic DM, et al
    ARMC5 Alterations in Patients With Sporadic Neuroendocrine Tumors and Multiple Endocrine Neoplasia Type 1 (MEN1).
    J Clin Endocrinol Metab. 2020;105.
    PubMed     Abstract available


    November 2020
  15. CAPEZZONE M, Sagnella A, Pilli T, Maino F, et al
    Role of Age at Diagnosis in Defining Potential Familial Non-Medullary Thyroid Cancer in Kindreds with Only Two Affected Members.
    J Clin Endocrinol Metab. 2020 Nov 11. pii: 5974121. doi: 10.1210.
    PubMed     Abstract available


  16. ENDO M, Porter K, Long C, Azaryan I, et al
    Features of Cytologically Indeterminate Molecularly Benign Nodules Treated With Surgery.
    J Clin Endocrinol Metab. 2020;105.
    PubMed     Abstract available


    October 2020
  17. WASSNER AJ
    Risk Stratification in Pediatric Thyroid Cancer: Growing Evidence for Individualized Therapy.
    J Clin Endocrinol Metab. 2020 Oct 30. pii: 5943497. doi: 10.1210.
    PubMed    


  18. BROOME DT, Naples R, Bailey R, Tekin Z, et al
    Use of Preoperative Imaging in Primary Hyperparathyroidism.
    J Clin Endocrinol Metab. 2020 Oct 29. pii: 5942949. doi: 10.1210.
    PubMed     Abstract available


  19. CAO XJ, Liu J, Zhu YL, Qi L, et al
    Efficacy and Safety of Thermal Ablation for Solitary T1bN0M0 Papillary Thyroid Carcinoma: A Multicenter Study.
    J Clin Endocrinol Metab. 2020 Oct 27. pii: 5940804. doi: 10.1210.
    PubMed     Abstract available


  20. YANG S, Jin C, Xu X
    Letter to the Editor from Shijie Yang et al: US-guided Microwave Ablation of Low-Risk Papillary Thyroid Microcarcinoma: Longer-Term Results of a Prospective Study.
    J Clin Endocrinol Metab. 2020 Oct 22. pii: 5936021. doi: 10.1210.
    PubMed    


    September 2020
  21. SHI X, Li CW, Tan LC, Wen SS, et al
    Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3 and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    J Clin Endocrinol Metab. 2020 Sep 30. pii: 5916419. doi: 10.1210.
    PubMed     Abstract available


  22. KITAHARA CM, Sosa JA, Shiels MS
    Influence of nomenclature changes on trends in papillary thyroid cancer incidence in the United States, 2000-2017.
    J Clin Endocrinol Metab. 2020 Sep 28. pii: 5912267. doi: 10.1210.
    PubMed     Abstract available


  23. RINGEL MD
    New Horizons: Emerging Therapies and Targets in Thyroid Cancer.
    J Clin Endocrinol Metab. 2020 Sep 25. pii: 5911817. doi: 10.1210.
    PubMed     Abstract available


  24. METOVIC J, Vignale C, Annaratone L, Osella-Abate S, et al
    The oncocytic variant of poorly differentiated thyroid carcinoma shows a specific immune-related gene expression profile.
    J Clin Endocrinol Metab. 2020 Sep 16. pii: 5906602. doi: 10.1210.
    PubMed     Abstract available


  25. ZHI J, Zhang P, Zhang W, Ruan X, et al
    Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing TsMHC-II-mediated Immune Recognition.
    J Clin Endocrinol Metab. 2020 Sep 16. pii: 5906618. doi: 10.1210.
    PubMed     Abstract available


  26. BUTTNER M, Locati LD, Pinto M, Araujo C, et al
    Quality of life in patients with hypoparathyroidism after treatment for thyroid cancer.
    J Clin Endocrinol Metab. 2020 Sep 11. pii: 5904489. doi: 10.1210.
    PubMed    


  27. SINGH P, Bhadada SK, Dahiya D, Arya AK, et al
    Reduced Calcium Sensing Receptor (CaSR) Expression Is Epigenetically Deregulated in Parathyroid Adenomas.
    J Clin Endocrinol Metab. 2020;105.
    PubMed     Abstract available


  28. FULLER S, Del Rivero J, Venzon D, Ilanchezhian M, et al
    Pulmonary Function in Patients With Multiple Endocrine Neoplasia 2B.
    J Clin Endocrinol Metab. 2020;105.
    PubMed     Abstract available


    August 2020
  29. IWADATE M, Mitsutake N, Matsuse M, Fukushima T, et al
    The clinicopathological results of thyroid cancer with BRAFV600E mutation in the young population of Fukushima.
    J Clin Endocrinol Metab. 2020 Aug 22. pii: 5895513. doi: 10.1210.
    PubMed     Abstract available


  30. SUGINO K, Nagahama M, Kitagawa W, Ohkuwa K, et al
    Distant metastasis in pediatric and adolescent differentiated thyroid cancer: Clinical outcomes and risk factor analyses.
    J Clin Endocrinol Metab. 2020 Aug 19. pii: 5894448. doi: 10.1210.
    PubMed     Abstract available


  31. CORDERO-BARREAL L, Caleiras E, Lopez de Maturana E, Monteagudo M, et al
    CD133 expression in medullary thyroid cancer cells identifies patients with poor prognosis.
    J Clin Endocrinol Metab. 2020 Aug 13. pii: 5892412. doi: 10.1210.
    PubMed     Abstract available


  32. CHANG DJ, Leung AM
    Who's Going to Manage the Thyroid Cancer?
    J Clin Endocrinol Metab. 2020 Aug 10. pii: 5890516. doi: 10.1210.
    PubMed    


  33. MATRONE A, Faranda A, Latrofa F, Gambale C, et al
    Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine.
    J Clin Endocrinol Metab. 2020;105.
    PubMed     Abstract available


  34. KIKUMORI T, Ichikawa T, Inaishi T, Miyajima N, et al
    Measurement of the AST to LD Ratio in Parathyroid Tissue Suspension Can Precisely Differentiate a Hyperfunctioning Parathyroid.
    J Clin Endocrinol Metab. 2020;105.
    PubMed     Abstract available


    July 2020
  35. LAN X, Cao J, Ye K, Zhang C, et al
    TCR-seq identifies distinct repertoires of distant metastatic and non-distant metastatic thyroid tumors.
    J Clin Endocrinol Metab. 2020 Jul 16. pii: 5872586. doi: 10.1210.
    PubMed     Abstract available


  36. RADHAKRISHNAN A, Reyes-Gastelum D, Gay B, Hawley ST, et al
    Primary care provider involvement in thyroid cancer survivorship care.
    J Clin Endocrinol Metab. 2020 Jul 8. pii: 5868790. doi: 10.1210.
    PubMed     Abstract available


  37. ALEXANDER EK
    Utility of Minimally Invasive Treatment for Papillary Microcarcinoma, Acknowledging Most Require No Treatment at All.
    J Clin Endocrinol Metab. 2020;105.
    PubMed    


  38. PITOIA F, Smulever A, Jerkovich F
    "Letter to the Editor: Foundation OneTM Genomic Interrogation of Thyroid Cancers in Patients with Metastatic Disease Requiring Systemic Therapy".
    J Clin Endocrinol Metab. 2020 Jul 1. pii: 5865799. doi: 10.1210.
    PubMed    


    June 2020
  39. PACINI F
    Does microscopic extrathyroidal extension confer an higher risk of recurrence in patients with well differentiated thyroid cancer?
    J Clin Endocrinol Metab. 2020 Jun 29. pii: 5864721. doi: 10.1210.
    PubMed    


  40. HONG Z, Xin X, Ying C, Yi L, et al
    Chaperone-mediated autophagy governs progression of papillary thyroid carcinoma via PPARgamma-SDF1/CXCR4 signaling.
    J Clin Endocrinol Metab. 2020 Jun 18. pii: 5859150. doi: 10.1210.
    PubMed     Abstract available


  41. ALZAHRANI AS, Alswailem M, Alswailem AA, Al-Hindi H, et al
    Genetic Alterations in Pediatric Thyroid Cancer Using a Comprehensive Childhood Cancer Gene Panel.
    J Clin Endocrinol Metab. 2020 Jun 18. pii: 5859128. doi: 10.1210.
    PubMed     Abstract available


  42. BRADLEY D
    Obesity, Thyroid Nodularity, and Thyroid Cancer: Epiphenomenon or Cause?
    J Clin Endocrinol Metab. 2020 Jun 11. pii: 5856160. doi: 10.1210.
    PubMed    


  43. CHEN L, Xiong L, Hong S, Li J, et al
    Circulating myeloid-derived suppressor cells facilitate invasion of thyroid cancer cells by repressing miR-486-3p.
    J Clin Endocrinol Metab. 2020 Jun 3. pii: 5850994. doi: 10.1210.
    PubMed     Abstract available


  44. GRANI G, Sponziello M, Pecce V, Ramundo V, et al
    Contemporary thyroid nodule evaluation and management.
    J Clin Endocrinol Metab. 2020 Jun 3. pii: 5850848. doi: 10.1210.
    PubMed     Abstract available


    May 2020
  45. JUNG SN, Kang YE, Lee GH, Liu L, et al
    Brn3a/Pou4f1 functions as a tumor suppressor by targeting c-MET/STAT3 signaling in thyroid cancer.
    J Clin Endocrinol Metab. 2020 May 31. pii: 5849340. doi: 10.1210.
    PubMed     Abstract available


  46. CAMPBELL PJ, Kendrew P, Lewer M, Lim EM, et al
    Response to Letter to the Editor: Changes in thyroid function across adolescence: a longitudinal study.
    J Clin Endocrinol Metab. 2020 May 27. pii: 5847824. doi: 10.1210.
    PubMed    


  47. RAVEROT V, Perrin P, Borson-Chazot F
    Letter to the Editor: "Changes in Thyroid Function Across Adolescence: a Longitudinal Study".
    J Clin Endocrinol Metab. 2020 May 27. pii: 5847823. doi: 10.1210.
    PubMed    


  48. WANG G, Wang S, Zhang M, Li Y, et al
    EV PD-L1 is correlated with clinical features and contributes to T cell suppression in pediatric thyroid cancer.
    J Clin Endocrinol Metab. 2020 May 27. pii: 5847668. doi: 10.1210.
    PubMed     Abstract available


  49. INIGUEZ-ARIZA NM, Jasim S, Ryder MM, Chintakuntlawar AV, et al
    Foundation OneTM Genomic Interrogation of Thyroid Cancers in Patients with Metastatic Disease Requiring Systemic Therapy.
    J Clin Endocrinol Metab. 2020 May 18. pii: 5839873. doi: 10.1210.
    PubMed     Abstract available


  50. MAURI G, Giugliano G, Maria Cecilia M, Luca S, et al
    Letter to the Editor: Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center.
    J Clin Endocrinol Metab. 2020 May 12. pii: 5836400. doi: 10.1210.
    PubMed    


  51. MOLINARO E, Campopiano C, Elisei R
    Response to Letter to the Editor: Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center.
    J Clin Endocrinol Metab. 2020 May 12. pii: 5836401. doi: 10.1210.
    PubMed    


  52. FUSSEY JM, Beaumont RN, Wood AR, Vaidya B, et al
    Does obesity cause thyroid cancer? A Mendelian randomization study.
    J Clin Endocrinol Metab. 2020 May 11. pii: 5835841. doi: 10.1210.
    PubMed     Abstract available


  53. PAPARODIS RD, Bantouna D, Karvounis E, Imam S, et al
    Higher TSH is not associated with thyroid cancer risk in the presence of thyroid autoimmunity.
    J Clin Endocrinol Metab. 2020 May 11. pii: 5835732. doi: 10.1210.
    PubMed     Abstract available


  54. VIGNERI R, Malandrino P, Russo M
    Is thyroid cancer increasing in incidence and aggressiveness?
    J Clin Endocrinol Metab. 2020 May 4. pii: 5830805. doi: 10.1210.
    PubMed    


    April 2020
  55. LIN HT, Liu FC, Lin SF, Kuo CF, et al
    Familial aggregation and heritability of non-medullary thyroid cancer in an Asia population: A nationwide cohort study.
    J Clin Endocrinol Metab. 2020 Apr 25. pii: 5825279. doi: 10.1210.
    PubMed     Abstract available


  56. LONG M, Zhu Y, Chen Z, Lin S, et al
    Lysine-Specific Demethylase 1 Affects the Progression of Papillary Thyroid Carcinoma via HIF1alpha and microRNA-146a.
    J Clin Endocrinol Metab. 2020 Apr 18. pii: 5821525. doi: 10.1210.
    PubMed     Abstract available


  57. PANATO C, Vaccarella S, Dal Maso L, Basu P, et al
    Thyroid cancer incidence in India between 2006 and 2014 and impact of overdiagnosis.
    J Clin Endocrinol Metab. 2020 Apr 16. pii: 5820802. doi: 10.1210.
    PubMed     Abstract available


    March 2020
  58. RITTER A, Mizrachi A, Bachar G, Vainer I, et al
    Detecting Recurrence Following Lobectomy for Thyroid Cancer: Role of Thyroglobulin and Thyroglobulin Antibodies.
    J Clin Endocrinol Metab. 2020 Mar 27. pii: 5812602. doi: 10.1210.
    PubMed     Abstract available


  59. YUE WW, Qi L, Wang DD, Yu SJ, et al
    US-guided Microwave ablation of Low-risk Papillary thyroid Microcarcinoma: Longer-term results of a Prospective study.
    J Clin Endocrinol Metab. 2020 Mar 21. pii: 5810812. doi: 10.1210.
    PubMed     Abstract available


  60. YAN KL, Li S, Tseng CH, Kim J, et al
    Rising Incidence and Incidence-Based Mortality of Thyroid Cancer in California, 2000-2017.
    J Clin Endocrinol Metab. 2020 Mar 13. pii: 5804233. doi: 10.1210.
    PubMed     Abstract available


    February 2020
  61. VOGEL T, Wendler J, Frank-Raue K, Kreissl MC, et al
    Bone metastases in medullary thyroid carcinoma: high morbidity and poor prognosis associated with osteolytic morphology.
    J Clin Endocrinol Metab. 2020 Feb 19. pii: 5740219. doi: 10.1210.
    PubMed     Abstract available


    December 2019
  62. HINDIE E, Ain KB, Zerdoud S, Avram AM, et al
    Association of Radioactive Iodine Treatment of Hyperthyroidism with Cancer Mortality: an Unjustified Warning?
    J Clin Endocrinol Metab. 2019 Dec 26. pii: 5687008. doi: 10.1210.
    PubMed    


  63. MATRONE A, Ceccarini G, Beghini M, Ferrari F, et al
    Potential impact of BMI on the aggressiveness of presentation and clinical outcome of Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2019 Dec 26. pii: 5687038. doi: 10.1210.
    PubMed     Abstract available


    November 2019
  64. ANGELL TE
    Insights from a real-world study of molecular test performance for indeterminate thyroid nodules.
    J Clin Endocrinol Metab. 2019 Nov 25. pii: 5639764. doi: 10.1210.
    PubMed    


  65. CASTELLANA M, Castellana C, Treglia G, Giorgino F, et al
    Performance of five ultrasound risk stratification systems in selecting thyroid nodules for FNA. A meta-analysis.
    J Clin Endocrinol Metab. 2019 Nov 6. pii: 5613652. doi: 10.1210.
    PubMed     Abstract available


    October 2019
  66. ASARE EA, Perrier ND
    Letter to the Editor: "An Analysis of the American Joint Committee on Cancer 8th Edition T Staging System for Papillary Thyroid Carcinoma".
    J Clin Endocrinol Metab. 2019 Oct 28. pii: 5607922. doi: 10.1210.
    PubMed    


  67. SIPOS JA
    The thyroid nodule conundrum: evaluate or leave it alone?
    J Clin Endocrinol Metab. 2019 Oct 28. pii: 5607891. doi: 10.1210.
    PubMed    


  68. DURANTE C, Grani G
    Clinically silent thyroid cancers: drop those needles and scalpels!
    J Clin Endocrinol Metab. 2019 Oct 28. pii: 5607921. doi: 10.1210.
    PubMed    


  69. VAN VELSEN EFS, Stegenga MT, van Kemenade FJ, Kam BLR, et al
    Evaluation of the 2015 ATA Guidelines in Patients with Distant Metastatic Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2019 Oct 28. pii: 5607901. doi: 10.1210.
    PubMed     Abstract available


  70. SAN MARTIN VT, Lawrence L, Bena J, Madhun NZ, et al
    Real World Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
    J Clin Endocrinol Metab. 2019 Oct 26. pii: 5607535. doi: 10.1210.
    PubMed     Abstract available


  71. MOLINARO E, Campopiano MC, Pieruzzi L, Matrone A, et al
    Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center.
    J Clin Endocrinol Metab. 2019 Oct 25. pii: 5607347. doi: 10.1210.
    PubMed     Abstract available


  72. HUGEN N, Sloot YJE, Netea-Maier RT, van de Water C, et al
    Divergent metastatic patterns between subtypes of thyroid carcinoma results from the nationwide Dutch pathology registry.
    J Clin Endocrinol Metab. 2019 Oct 23. pii: 5602698. doi: 10.1210.
    PubMed     Abstract available


    August 2019
  73. ESFANDIARI NH, Hughes DT, Reyes-Gastelum D, Ward KC, et al
    Factors Associated with Diagnosis and Treatment of Thyroid Microcarcinomas.
    J Clin Endocrinol Metab. 2019 Aug 15. pii: 5550196. doi: 10.1210/jc.2019-01219.
    PubMed     Abstract available


    July 2019
  74. ANGELL TE, Maurer R, Wang Z, Kim MI, et al
    A Cohort Analysis of Clinical and Ultrasound Variables Predicting Cancer Risk in 20,001 Consecutive Thyroid Nodules.
    J Clin Endocrinol Metab. 2019 Jul 16. pii: 5532036. doi: 10.1210/jc.2019-00664.
    PubMed     Abstract available


  75. CHONG ST, Tan KM, Kok CYL, Guan SP, et al
    IL13RA2 is differentially regulated in Papillary Thyroid Carcinoma versus Follicular Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2019 Jul 10. pii: 5530249. doi: 10.1210/jc.2019-00040.
    PubMed     Abstract available


    June 2019
  76. GRANI G, Ramundo V, Falcone R, Lamartina L, et al
    Thyroid cancer patients with no evidence of disease: the need for repeat neck ultrasound.
    J Clin Endocrinol Metab. 2019 Jun 17. pii: 5516551. doi: 10.1210/jc.2019-00962.
    PubMed     Abstract available


    May 2019
  77. RAUE F, Bruckner T, Frank-Raue K
    Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center.
    J Clin Endocrinol Metab. 2019 May 30. pii: 5506437. doi: 10.1210/jc.2019-00516.
    PubMed     Abstract available


  78. LIU Z, Shen X, Liu R, Zhu G, et al
    Stage II Differentiated Thyroid Cancer Is a High-risk Disease in Patients <45/55 Years Old.
    J Clin Endocrinol Metab. 2019 May 22. pii: 5492492. doi: 10.1210/jc.2018-02809.
    PubMed     Abstract available


  79. NISHIKAWA Y, Kohno A, Takahashi Y, Suzuki C, et al
    Stable Iodine Distribution Among Children After the 2011 Fukushima Nuclear Disaster in Japan: An Observational Study.
    J Clin Endocrinol Metab. 2019;104:1658-1666.
    PubMed     Abstract available


    April 2019
  80. SAPUPPO G, Tavarelli M, Belfiore A, Vigneri R, et al
    Response to Letter to the Editor: [Time to Separate Persistent from Recurrent Differentiated Thyroid Cancer: Different Conditions with Different outcomes].
    J Clin Endocrinol Metab. 2019 Apr 24. pii: 5476510. doi: 10.1210/jc.2019-00851.
    PubMed    


  81. BURMEISTER LA, Drake T
    "Letter to the Editor: [Time to Separate Persistent from Recurrent Differentiated Thyroid Cancer: Different Conditions with Different outcomes]".
    J Clin Endocrinol Metab. 2019 Apr 24. pii: 5476515. doi: 10.1210/jc.2019-00634.
    PubMed    


  82. MA B, Jiang H, Wen D, Hu J, et al
    Transcriptome analyses identify a metabolic gene signature indicative of dedifferentiation of papillary thyroid cancer.
    J Clin Endocrinol Metab. 2019 Apr 3. pii: 5425396. doi: 10.1210/jc.2018-02686.
    PubMed     Abstract available


    March 2019
  83. GIANNINI R, Moretti S, Ugolini C, Macerola E, et al
    Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: an ATC-like and a PDTC-like.
    J Clin Endocrinol Metab. 2019 Mar 18. pii: 5381919. doi: 10.1210/jc.2018-01167.
    PubMed     Abstract available


  84. DEANDREA M, Trimboli P, Garino F, Mormile A, et al
    Long Term Efficacy of a Single Session RFA of Benign Thyroid Nodules: A Longitudinal 5-Year Observational Study.
    J Clin Endocrinol Metab. 2019 Mar 12. pii: 5372729. doi: 10.1210/jc.2018-02808.
    PubMed     Abstract available


  85. COLOMBO C, De Leo S, Di Stefano M, Vannucchi G, et al
    Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.
    J Clin Endocrinol Metab. 2019;104:779-784.
    PubMed     Abstract available


    February 2019
  86. LI J, An C, Zheng H, Lei T, et al
    Leukocyte telomere length and risk of papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2019 Feb 28. pii: 5365821. doi: 10.1210/jc.2018-02471.
    PubMed     Abstract available


  87. BARRES B, Kelly A, Kwiatkowski F, Batisse-Lignier M, et al
    Stimulated thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
    J Clin Endocrinol Metab. 2019 Feb 20. pii: 5342942. doi: 10.1210/jc.2018-02680.
    PubMed     Abstract available


    November 2018
  88. WIRTH LJ
    Still Perfecting Radioiodine in Thyroid Cancer, After All These Years.
    J Clin Endocrinol Metab. 2018 Nov 19. pii: 5185197. doi: 10.1210/jc.2018-02437.
    PubMed    


  89. HATCH M, Brenner AV, Cahoon EK, Drozdovitch V, et al
    Thyroid Cancer and Benign Nodules after Exposure In Utero to Fallout from Chernobyl.
    J Clin Endocrinol Metab. 2018 Nov 16. pii: 5184192. doi: 10.1210/jc.2018-00847.
    PubMed     Abstract available


  90. LEENHARDT L, Leboulleux S, Bournaud C, Zerdoud S, et al
    Recombinant thyrotropin vs levothyroxine withdrawal in 131I therapy of N1 thyroid cancer: a large matched cohort study (ThyrNod).
    J Clin Endocrinol Metab. 2018 Nov 5. pii: 5155461. doi: 10.1210/jc.2018-01589.
    PubMed     Abstract available


    October 2018
  91. HAYMART MR, Banerjee M, Reyes-Gastelum D, Caoili E, et al
    Thyroid Ultrasound and the Increase in Diagnosis of Low-risk Thyroid Cancer.
    J Clin Endocrinol Metab. 2018 Oct 16. pii: 5128913. doi: 10.1210/jc.2018-01933.
    PubMed     Abstract available


  92. GRANI G, Lamartina L, Ascoli V, Bosco D, et al
    Reducing the number of unnecessary thyroid biopsies while improving diagnostic accuracy: towards the "right" TIRADS.
    J Clin Endocrinol Metab. 2018 Oct 8. pii: 5115830. doi: 10.1210/jc.2018-01674.
    PubMed     Abstract available


    September 2018
  93. ALZAHRANI AS, Alswailem M, Moria Y, Almutairi R, et al
    Lung Metastasis in Pediatric Thyroid Cancer: Radiological Pattern, Molecular Genetics, Response to Therapy and Outcome.
    J Clin Endocrinol Metab. 2018 Sep 28. pii: 5107762. doi: 10.1210/jc.2018-01690.
    PubMed     Abstract available


  94. DUNN LA, Sherman EJ, Baxi SS, Tchekmedyian V, et al
    Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
    J Clin Endocrinol Metab. 2018 Sep 25. pii: 5105931. doi: 10.1210/jc.2018-01478.
    PubMed     Abstract available


    August 2018
  95. PARK SY, Cho YY, Kim HI, Choe JH, et al
    Clinical validation of the prognostic stage groups of the eighth edition TNM staging for medullary thyroid carcinoma.
    J Clin Endocrinol Metab. 2018 Aug 17. pii: 5075160. doi: 10.1210/jc.2018-01386.
    PubMed     Abstract available


  96. BOUCAI L, Falcone J, Ukena J, Coombs CC, et al
    Radioactive iodine-related clonal hematopoiesis in thyroid cancer is common and associated with decreased survival.
    J Clin Endocrinol Metab. 2018 Aug 17. pii: 5075165. doi: 10.1210/jc.2018-00803.
    PubMed     Abstract available


  97. HWANGBO Y, Lee EK, Son HY, Im SW, et al
    Genome-wide Association Study Reveals Distinct Genetic Susceptibility of Thyroid Nodules from Thyroid Cancer.
    J Clin Endocrinol Metab. 2018 Aug 6. pii: 5066513. doi: 10.1210/jc.2017-02439.
    PubMed     Abstract available


    July 2018
  98. ZHANG X, Wang C, Lin Y
    Pilot Dose Comparison of Apatinib in Chinese Progressive Radioiodine Refractory Differentiated Thyroid Cancer Patients.
    J Clin Endocrinol Metab. 2018 Jul 20. pii: 5056320. doi: 10.1210/jc.2018-00381.
    PubMed     Abstract available


  99. KLUBO-GWIEZDZINSKA J, Wartofsky L
    Commentary on: "Gene Expression Classifier versus Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules".
    J Clin Endocrinol Metab. 2018 Jul 18. pii: 5055545. doi: 10.1210/jc.2018-01081.
    PubMed    


  100. TURNBULL C, Loveday C, Izatt L, Ellard S, et al
    Response to Letter to the Editor regarding : "p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer" from Andreas Machens and Henning Dralle.
    J Clin Endocrinol Metab. 2018 Jul 18. pii: 5055548. doi: 10.1210/jc.2018-01094.
    PubMed    


  101. JABER T, Waguespack SG, Cabanillas ME, Elbanan M, et al
    Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
    J Clin Endocrinol Metab. 2018 Jul 18. pii: 5055540. doi: 10.1210/jc.2018-00612.
    PubMed     Abstract available


  102. PANDYA A, Caoili EM, Jawad-Makki F, Wasnik AP, et al
    Limitations of the 2015 ATA Guidelines for Prediction of Thyroid Cancer: A Review of 1,947 Consecutive Aspirations.
    J Clin Endocrinol Metab. 2018 Jul 3. pii: 5047770. doi: 10.1210/jc.2018-00792.
    PubMed     Abstract available


  103. CHERELLA CE, Feldman HA, Hollowell M, Richman DM, et al
    Natural History and Outcomes of Cytologically Benign Thyroid Nodules in Children.
    J Clin Endocrinol Metab. 2018 Jul 2. pii: 5047287. doi: 10.1210/jc.2018-00895.
    PubMed     Abstract available


    June 2018
  104. MACHENS A, Dralle H
    Letter to the Editor: "p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer".
    J Clin Endocrinol Metab. 2018 Jun 26. pii: 5043208. doi: 10.1210/jc.2018-00906.
    PubMed    


  105. KIM K, Kim IJ, Pak K, Kim SJ, et al
    Evaluation of bone mineral density using DXA and central QCT in postmenopausal patients under thyrotropin suppressive therapy.
    J Clin Endocrinol Metab. 2018 Jun 21. pii: 5041930. doi: 10.1210/jc.2017-02704.
    PubMed     Abstract available



  106. CORRIGENDUM FOR "DICER1 mutations are frequent in adolescent-onset papillary thyroid carcinoma".
    J Clin Endocrinol Metab. 2018 Jun 4. pii: 5032648. doi: 10.1210/jc.2018-01190.
    PubMed    


  107. SADOWSKI SM, Pusztaszeri M, Brulhart-Meynet MC, Petrenko V, et al
    Identification of Differential Transcriptional Patterns in Primary and Secondary Hyperparathyroidism.
    J Clin Endocrinol Metab. 2018;103:2189-2198.
    PubMed     Abstract available


    May 2018
  108. PARK J, Blackburn BE, Ganz PA, Rowe K, et al
    Risk Factors for Cardiovascular Disease among Thyroid Cancer Survivors: Findings from the Utah Cancer Survivors Study.
    J Clin Endocrinol Metab. 2018 May 29. pii: 5005948. doi: 10.1210/jc.2017-02629.
    PubMed     Abstract available


  109. CASTRONEVES LA, Coura Filho G, de Freitas RMC, Salles R, et al
    Comparison of 68Ga PET/CT to other imaging studies in Medullary Thyroid Cancer: superiority in detecting bone metastases.
    J Clin Endocrinol Metab. 2018 May 28. pii: 5005944. doi: 10.1210/jc.2018-00193.
    PubMed     Abstract available


  110. MARLOW LA, Rohl SD, Miller JL, Knauf JA, et al
    Methodology, criteria and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts.
    J Clin Endocrinol Metab. 2018 May 25. pii: 5003409. doi: 10.1210/jc.2017-01845.
    PubMed     Abstract available


  111. MACFARLAND SP, Bauer AJ, Adzick NS, Surrey LF, et al
    Disease Burden and Outcome in Pediatric and Young Adults with Concurrent Graves Disease and Differentiated Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2018 May 18. pii: 4998998. doi: 10.1210/jc.2018-00026.
    PubMed     Abstract available


  112. BANERJEE M, Reyes-Gastelum D, Haymart MR
    Treatment-free Survival in Patients with Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2018 May 16. pii: 4996515. doi: 10.1210/jc.2018-00511.
    PubMed     Abstract available


  113. NICOLSON NG, Murtha TD, Dong W, Paulsson JO, et al
    Comprehensive Genetic Analysis of Follicular Thyroid Carcinoma Predicts Prognosis Independent of Histology.
    J Clin Endocrinol Metab. 2018 May 2. pii: 4990776. doi: 10.1210/jc.2018-00277.
    PubMed     Abstract available


  114. LIVHITS M
    Response to Letter to the Editor: "Decreasing Use of Radioactive Iodine for Low-Risk Thyroid Cancer in California, 1999 to 2015".
    J Clin Endocrinol Metab. 2018;103:2073.
    PubMed    


  115. YLLI D, Burman KD, Van Nostrand D, Wartofsky L, et al
    Eliminating the Age Cutoff in Staging of Differentiated Thyroid Cancer: The Safest Road?
    J Clin Endocrinol Metab. 2018;103:1813-1817.
    PubMed     Abstract available


    April 2018
  116. TRAN B DR., Roshan D Mr., Abraham E Dr., Wang L Dr., et al
    An Analysis of The American Joint Committee on Cancer 8th Edition T Staging System for Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2018 Apr 16. pii: 4970148. doi: 10.1210/jc.2017-02551.
    PubMed     Abstract available


  117. MAINO F, Forleo R, Martinelli M, Fralassi N, et al
    Prospective Validation of ATA and ETA Sonographic Pattern Risk of Thyroid Nodules Selected for FNAC.
    J Clin Endocrinol Metab. 2018 Apr 16. pii: 4970151. doi: 10.1210/jc.2018-00274.
    PubMed     Abstract available


  118. JABER T, Hyde SM, Cote GJ, Grubbs EG, et al
    A Homozygous RET K666N Genotype With an MEN2A Phenotype.
    J Clin Endocrinol Metab. 2018;103:1269-1272.
    PubMed     Abstract available


    March 2018
  119. KITAHARA CM, Farkas DKR, Jorgensen JOL, Cronin-Fenton D, et al
    Benign Thyroid Diseases and Risk of Thyroid Cancer: A Nationwide Cohort Study.
    J Clin Endocrinol Metab. 2018 Mar 23. pii: 4951500. doi: 10.1210/jc.2017-02599.
    PubMed     Abstract available


  120. LIVHITS MJ, Kuo EJ, Leung AM, Rao J, et al
    Gene Expression Classifier versus Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules.
    J Clin Endocrinol Metab. 2018 Mar 23. pii: 4951503. doi: 10.1210/jc.2017-02754.
    PubMed     Abstract available


  121. LOVEDAY C, Josephs K, Chubb D, Gunning A, et al
    p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer.
    J Clin Endocrinol Metab. 2018 Mar 23. pii: 4951497. doi: 10.1210/jc.2017-02529.
    PubMed     Abstract available


  122. WU D, Guan H
    Letter to the Editor: "Decreasing use of radioactive iodine for low risk thyroid cancer in California, 1999-2015".
    J Clin Endocrinol Metab. 2018 Mar 13. pii: 4931670. doi: 10.1210/jc.2018-00333.
    PubMed    


  123. GANNON AW, Langer JE, Bellah R, Ratcliffe S, et al
    Diagnostic Accuracy of Ultrasound with Color Flow Doppler in Children with Thyroid Nodules.
    J Clin Endocrinol Metab. 2018 Mar 12. pii: 4931064. doi: 10.1210/jc.2017-02464.
    PubMed     Abstract available


    February 2018
  124. WASSERMAN JD, Sabbaghian N, Fahiminiya S, Chami R, et al
    DICER1 mutations are frequent in adolescent-onset papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2018 Feb 21. pii: 4893697. doi: 10.1210/jc.2017-02698.
    PubMed     Abstract available


  125. SAMUELS SL, Surrey LF, Hawkes CP, Amberge M, et al
    Characteristics of Follicular Variant Papillary Thyroid Carcinoma in a Pediatric Cohort.
    J Clin Endocrinol Metab. 2018 Feb 8. pii: 4844750. doi: 10.1210/jc.2017-02454.
    PubMed     Abstract available


  126. PERSICHETTI A, Di Stasio E, Guglielmi R, Bizzarri G, et al
    Predictive Value of Malignancy of Thyroid Nodule Ultrasound Classification Systems. A Prospective Study.
    J Clin Endocrinol Metab. 2018 Feb 1. pii: 4834029. doi: 10.1210/jc.2017-01708.
    PubMed     Abstract available


    January 2018
  127. GIORDANO TJ, Haugen B, Sherman SI, Shah MH, et al
    Pioglitazone Therapy of PAX8-PPARgamma Fusion Protein Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2018 Jan 24. pii: 4822913. doi: 10.1210/jc.2017-02533.
    PubMed     Abstract available


  128. TARABICHI M, Antoniou A, Le Pennec S, Gacquer D, et al
    Distinctive desmoplastic 3D morphology associated with BRAFV600E in papillary thyroid cancers.
    J Clin Endocrinol Metab. 2018 Jan 12. pii: 4801233. doi: 10.1210/jc.2017-02279.
    PubMed     Abstract available


  129. RAUE F, Dralle H, Machens A, Bruckner T, et al
    Long-Term Survivorship in Multiple Endocrine Neoplasia Type 2B Diagnosed Before and in the New Millennium.
    J Clin Endocrinol Metab. 2018;103:235-243.
    PubMed     Abstract available


    December 2017
  130. PRATHEESHKUMAR P, Siraj AK, Divya SP, Parvathareddy SK, et al
    Downregulation of SKP2 in papillary thyroid cancer acts synergistically with TRAIL on inducing apoptosis via ROS.
    J Clin Endocrinol Metab. 2017 Dec 28. pii: 4780811. doi: 10.1210/jc.2017-02178.
    PubMed     Abstract available


  131. PARK KW, Wu JX, Du L, Leung AM, et al
    Decreasing use of radioactive iodine for low risk thyroid cancer in California, 1999-2015.
    J Clin Endocrinol Metab. 2017 Dec 15. pii: 4743227. doi: 10.1210/jc.2017-02269.
    PubMed     Abstract available


  132. SHIMURA H, Sobue T, Takahashi H, Yasumura S, et al
    Findings of thyroid ultrasound examination within three years after the Fukushima Nuclear Power Plant accident: The Fukushima Health Management Survey.
    J Clin Endocrinol Metab. 2017 Dec 14. pii: 4630428. doi: 10.1210/jc.2017-01603.
    PubMed     Abstract available


  133. RITTER A, Bachar G, Hirsch D, Benbassat C, et al
    Natural History of Contralateral Nodules after Lobectomy in Patients with Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2017 Dec 12. pii: 4731740. doi: 10.1210/jc.2017-01616.
    PubMed     Abstract available


  134. SHAH S, Boucai L
    Effect of Age on Response to Therapy and Mortality in Patients with Thyroid Cancer at High-Risk of Recurrence.
    J Clin Endocrinol Metab. 2017 Dec 6. pii: 4693942. doi: 10.1210/jc.2017-02255.
    PubMed     Abstract available


  135. VAN DER TUIN K, Tops CMJ, Adank MA, Cobben JM, et al
    CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism.
    J Clin Endocrinol Metab. 2017;102:4534-4540.
    PubMed     Abstract available


  136. KIM HI, Jang HW, Ahn HS, Ahn S, et al
    High serum TSH level is associated with progression of papillary thyroid microcarcinoma during active surveillance.
    J Clin Endocrinol Metab. 2017 Dec 1. pii: 4677373. doi: 10.1210/jc.2017-01775.
    PubMed     Abstract available


    November 2017
  137. WATANABE N, Narimatsu H, Noh JY, Iwaku K, et al
    Long-term outcomes of 107 cases of primary thyroid MALT lymphoma at a single medical institution in Japan.
    J Clin Endocrinol Metab. 2017 Nov 20. doi: 10.1210/jc.2017-01478.
    PubMed     Abstract available


  138. KLEIN HESSELINK EN, Zafon C, Villalmanzo N, Iglesias C, et al
    Increased global DNA hypomethylation in distant metastatic and dedifferentiated thyroid cancer.
    J Clin Endocrinol Metab. 2017 Nov 20. doi: 10.1210/jc.2017-01613.
    PubMed     Abstract available


  139. HE H, Li W, Liyanarachchi S, Wang Y, et al
    The role of NRG1 in the predisposition to papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2017 Nov 7. doi: 10.1210/jc.2017-01798.
    PubMed     Abstract available


  140. MAZZIOTTI G, Formenti AM, Frara S, Olivetti R, et al
    HIGH PREVALENCE OF RADIOLOGICAL VERTEBRAL FRACTURES IN WOMEN ON TSH-SUPPRESSIVE THERAPY FOR THYROID CARCINOMA.
    J Clin Endocrinol Metab. 2017 Nov 7. doi: 10.1210/jc.2017-01986.
    PubMed     Abstract available


  141. HIRSCH D, Gorshtein A, Robenshtok E, Masri-Iraqi H, et al
    Second Radioiodine Treatment: Limited Benefit for Differentiated Thyroid Cancer with Loforegional Persistent Disease.
    J Clin Endocrinol Metab. 2017 Nov 3. doi: 10.1210/jc.2017-01790.
    PubMed     Abstract available


  142. CASEY RT, Warren AY, Martin JE, Challis BG, et al
    Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review.
    J Clin Endocrinol Metab. 2017;102:4013-4022.
    PubMed     Abstract available


    October 2017

  143. CORRIGENDUM FOR Letter to the Editor: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness".
    J Clin Endocrinol Metab. 2017 Oct 24. doi: 10.1210/jc.2017-02312.
    PubMed    


  144. ANGELL TE, Vyas C, Medici M, Wang Z, et al
    Differential Growth Rates of Benign versus Malignant Thyroid Nodules.
    J Clin Endocrinol Metab. 2017 Oct 12. doi: 10.1210/jc.2017-01832.
    PubMed     Abstract available


  145. PRASONGSOOK N, Kumar A, Chintakuntlawar AV, Foote RL, et al
    Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Oct 5. doi: 10.1210/jc.2017-01180.
    PubMed     Abstract available


    September 2017
  146. VOSS RK, Grubbs EG
    Response to Letter: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness".
    J Clin Endocrinol Metab. 2017;102:3559.
    PubMed    


  147. CASTINETTI F, Whollk N
    Letter to the Editor: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness".
    J Clin Endocrinol Metab. 2017;102:3557-3558.
    PubMed    


  148. COTE GJ, Evers C, Hu MI, Grubbs EG, et al
    Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2017;102:3591-3599.
    PubMed     Abstract available


  149. VIOLA D, Giani C, Mazzeo S, Ugolini C, et al
    KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease.
    J Clin Endocrinol Metab. 2017;102:3091-3096.
    PubMed     Abstract available


    August 2017
  150. DOS REIS MB, Barros-Filho MC, Marchi FA, Beltrami CM, et al
    Prognostic classifier based on genome-wide DNA methylation profiling in well-differentiated thyroid tumors.
    J Clin Endocrinol Metab. 2017 Aug 16. doi: 10.1210/jc.2017-00881.
    PubMed     Abstract available


    July 2017
  151. FRENCH JD, Haugen BR
    Thyroid-Specific T Cells in Patients With Differentiated Thyroid Cancer: Implications for Immune-Based Therapies?
    J Clin Endocrinol Metab. 2017;102:2131-2132.
    PubMed    


    June 2017
  152. SZCZEPANEK-PARULSKA E, Zybek-Kocik A, Wartofsky L, Ruchala M, et al
    Thyroid hemiagenesis: incidence, clinical significance and genetic background.
    J Clin Endocrinol Metab. 2017 Jun 28. doi: 10.1210/jc.2017-00784.
    PubMed     Abstract available


  153. ROSSFELD KK, Justiniano SE, Ding H, Gong L, et al
    Biological evaluation of a novel fluorescent-imaging agent for medullary thyroid cancer in an orthotopic model.
    J Clin Endocrinol Metab. 2017 Jun 7. doi: 10.1210/jc.2017-00573.
    PubMed     Abstract available


  154. WANG F, Yu X, Shen X, Zhu G, et al
    The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Jun 5. doi: 10.1210/jc.2017-00277.
    PubMed     Abstract available


  155. MATHIESEN JS, Habra MA, Bassett JHD, Choudhury SM, et al
    Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.
    J Clin Endocrinol Metab. 2017;102:2069-2074.
    PubMed     Abstract available


  156. MOMESSO DP, Tuttle RM
    Response to Letter: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?
    J Clin Endocrinol Metab. 2017;102:2115-2116.
    PubMed    


  157. GIOVANELLA L, Cosma C, Plebani M
    Letter to the Editor: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?
    J Clin Endocrinol Metab. 2017;102:2113-2114.
    PubMed    


    May 2017
  158. LEE JJ, Wang TY, Liu CL, Chien MN, et al
    Dipeptidyl peptidase IV as a prognostic marker and therapeutic target in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2017 May 26. doi: 10.1210/jc.2017-00346.
    PubMed     Abstract available


  159. VOSS RK, Feng L, Lee JE, Perrier ND, et al
    Medullary Thyroid Carcinoma in MEN2A: ATA Moderate or High-Risk RET Mutations Do Not Predict Disease Aggressiveness
    J Clin Endocrinol Metab. 2017 May 9. doi: 10.1210/jc.2017-00317.
    PubMed     Abstract available


  160. IMAIZUMI M, Ohishi W, Nakashima E, Sera N, et al
    Thyroid dysfunction and autoimmune thyroid diseases among atomic-bomb survivors exposed in childhood.
    J Clin Endocrinol Metab. 2017 May 1. doi: 10.1210/jc.2017-00102.
    PubMed     Abstract available


  161. ELISEI R, Binchi F, Matrone A
    Response to Letter: "Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation".
    J Clin Endocrinol Metab. 2017;102:1785-1786.
    PubMed    


  162. GIOVANELLA L, Ceriani L, Trimboli P
    Letter to the Editor: "Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation".
    J Clin Endocrinol Metab. 2017;102:1783-1784.
    PubMed    


    April 2017
  163. PAPALEONTIOU M, Hughes DT, Guo C, Banerjee M, et al
    Population-Based Assessment of Complications following Surgery for Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Apr 28. doi: 10.1210/jc.2017-00255.
    PubMed     Abstract available


  164. WASSNER AJ, Della Vecchia M, Jarolim P, Feldman HA, et al
    Prevalence and Significance of Thyroglobulin Antibodies in Pediatric Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Apr 10. doi: 10.1210/jc.2017-00286.
    PubMed     Abstract available


    March 2017
  165. CAHOON EK, Nadirov EA, Polanskaya ON, Yauseyenka VV, et al
    Risk of thyroid nodules in residents of Belarus exposed to Chernobyl fallout as children and adolescents.
    J Clin Endocrinol Metab. 2017 Mar 22. doi: 10.1210/jc.2016-3842.
    PubMed     Abstract available


  166. LUBIN JH, Adams MJ, Shore R, Holmberg E, et al
    Thyroid cancer following childhood low dose radiation exposure: a pooled analysis of nine cohorts.
    J Clin Endocrinol Metab. 2017 Mar 8. doi: 10.1210/jc.2016-3529.
    PubMed     Abstract available


  167. MELO M, Gaspar da Rocha A, Batista R, Vinagre J, et al
    TERT, BRAF and NRAS in primary thyroid cancer and metastatic disease.
    J Clin Endocrinol Metab. 2017 Mar 6. doi: 10.1210/jc.2016-2785.
    PubMed     Abstract available


  168. KWON H, Oh HS, Kim M, Park S, et al
    Active Surveillance for Patients with Papillary Thyroid Microcarcinoma: A Single Center's Experience in Korea.
    J Clin Endocrinol Metab. 2017 Mar 3. doi: 10.1210/jc.2016-4026.
    PubMed     Abstract available


    February 2017
  169. KIM TH, Ki CS, Kim HS, Kim K, et al
    Refining dynamic risk stratification and prognostic groups for differentiated thyroid cancer with TERT promoter mutations.
    J Clin Endocrinol Metab. 2017 Feb 28. doi: 10.1210/jc.2016-3434.
    PubMed     Abstract available


  170. KHAN NE, Bauer AJ, Schultz KA, Doros L, et al
    Quantification of thyroid cancer and multinodular goiter risk in the DICER1 syndrome: a family-based cohort study.
    J Clin Endocrinol Metab. 2017 Feb 2. doi: 10.1210/jc.2016-2954.
    PubMed     Abstract available


    January 2017
  171. CHOKSI P, Papaleontiou M, Guo C, Worden F, et al
    Skeletal Complications and Mortality in Thyroid Cancer: A Population-Based Study.
    J Clin Endocrinol Metab. 2017 Jan 25. doi: 10.1210/jc.2016-3906.
    PubMed     Abstract available


  172. PARK S, Jeon MJ, Song E, Oh HS, et al
    Clinical Features of Early and Late Postoperative Hypothyroidism after Lobectomy.
    J Clin Endocrinol Metab. 2017 Jan 11. doi: 10.1210/jc.2016-3597.
    PubMed     Abstract available


    December 2016
  173. BAGHERI-YARMAND R, Williams MD, Grubbs EG, Gagel RF, et al
    ATF4 Targets RET for Degradation and is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Dec 9:jc20162878.
    PubMed     Abstract available


  174. MATRONE A, Gambale C, Piaggi P, Viola D, et al
    Postoperative thyroglobulin and neck ultrasound in the risk re-stratification and decision to perform 131I ablation.
    J Clin Endocrinol Metab. 2016 Dec 8:jc20162860.
    PubMed     Abstract available


    November 2016
  175. SCHNEIDER TC, de Wit D, Links TP, van Erp NP, et al
    Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.
    J Clin Endocrinol Metab. 2016 Nov 21:jc20162525.
    PubMed     Abstract available


  176. EHLERS M, Kuebart A, Hautzel H, Enczmann J, et al
    Epitope-specific antitumor immunity suppresses tumor spread in papillary thyroid cancer.
    J Clin Endocrinol Metab. 2016 Nov 18:jc20162469.
    PubMed     Abstract available


  177. MAROTTA V, Sciammarella C, Capasso M, Testori A, et al
    Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2016 Nov 16:jc20162555.
    PubMed     Abstract available


  178. SUNG TY, Jeon MJ, Lee YH, Lee YM, et al
    Initial and Dynamic Risk Stratification of Pediatric Patients with Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Nov 3:jc20162666.
    PubMed     Abstract available


    October 2016
  179. WANG W, Kang H, Zhao Y, Min I, et al
    Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib.
    J Clin Endocrinol Metab. 2016 Oct 18:jc20161999.
    PubMed     Abstract available


  180. ZHANG Y, Sui F, Ma J, Ren X, et al
    Positive Feedback Loops between NrCAM and Major Signaling Pathways Contribute to Thyroid Tumorigenesis.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20161677.
    PubMed     Abstract available


  181. HWANGBO Y, Kim JM, Park YJ, Lee EK, et al
    Long-term Recurrence of Small Papillary Thyroid Cancer and Its Risk Factors in a Korean Multicenter Study.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20162287.
    PubMed     Abstract available


    September 2016
  182. KIM SW, Song SH, Lee HS, Noh WJ, et al
    Intraoperative Real-Time Localization of Normal Parathyroid Glands with Autofluorescence Imaging.
    J Clin Endocrinol Metab. 2016 Sep 20:jc20162558.
    PubMed     Abstract available


  183. UCHINO S, Ishikawa H, Miyauchi A, Hirokawa M, et al
    Age- and Gender-Specific Risk of Thyroid Cancer in Patients with Familial Adenomatous Polyposis.
    J Clin Endocrinol Metab. 2016 Sep 13:jc20162043.
    PubMed     Abstract available


    August 2016
  184. YU XU J, Handy B, Michaelis CL, Waguespack SG, et al
    Detection and Prognostic Significance of Circulating Tumor Cells in Patients with Metastatic Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Aug 30:jc20162567.
    PubMed     Abstract available


  185. ROBINSON B, Schlumberger M, Wirth LJ, Dutcus CE, et al
    Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Aug 22:jc20153989.
    PubMed     Abstract available


  186. HOLLINGSWORTH B, Senter L, Zhang X, Brock GN, et al
    Risk Factors of 131I-Induced Salivary Gland Damage in Thyroid Cancer Patients.
    J Clin Endocrinol Metab. 2016 Aug 17:jc20161605.
    PubMed     Abstract available


  187. PALERMO A, Mangiameli G, Tabacco G, Longo F, et al
    PTH(1-34) for the primary prevention of post-thyroidectomy hypocalcemia: the THYPOS trial.
    J Clin Endocrinol Metab. 2016 Aug 15:jc20162530.
    PubMed     Abstract available


  188. LY S, Frates MC, Benson CB, Peters HE, et al
    Features and outcome of autonomous thyroid nodules in children: 31 consecutive patients seen at a single center.
    J Clin Endocrinol Metab. 2016 Aug 8:jc20161779.
    PubMed     Abstract available


  189. LABOURIER E
    Letter to the Editor: The Value of Molecular Testing for Effective Management of Patients With Indeterminate Thyroid Nodules.
    J Clin Endocrinol Metab. 2016;101:L76-7.
    PubMed    


    July 2016
  190. LIYANARACHCHI S, Li W, Yan P, Bundschuh R, et al
    Genome-wide expression screening discloses long noncoding RNAs involved in thyroid carcinogenesis.
    J Clin Endocrinol Metab. 2016 Jul 26:jc20161991.
    PubMed     Abstract available


  191. LUO J, Hendryx M, Manson JE, Liang X, et al
    Hysterectomy, oophorectomy and risk of thyroid cancer.
    J Clin Endocrinol Metab. 2016 Jul 26:jc20162011.
    PubMed     Abstract available


    May 2016
  192. LAMARTINA L, Grani G, Biffoni M, Giacomelli L, et al
    Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2016 May 17:jc20161440.
    PubMed     Abstract available


    April 2016
  193. LAMARTINA L, Ippolito S, Danis M, Bidault F, et al
    Anti-angiogenic Tyrosine Kinase Inhibitors: occurrence and risk factors of hemoptysis in refractory thyroid cancer.
    J Clin Endocrinol Metab. 2016 Apr 15:jc20154391.
    PubMed     Abstract available


  194. BASTMAN JJ, Serracino HS, Zhu Y, Koenig MR, et al
    Tumor-infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Apr 5:jc20154227.
    PubMed     Abstract available


    March 2016
  195. MOMESSO DP, Vaisman F, Yang SP, Bulzico DA, et al
    DYNAMIC RISK STRATIFICATION IN DIFFERENTIATED THYROID CANCER PATIENTS TREATED WITHOUT RADIOACTIVE IODINE.
    J Clin Endocrinol Metab. 2016 Mar 29:jc20154290.
    PubMed     Abstract available


  196. BURCH HB, Burman KD, Cooper DS, Hennessey JV, et al
    A 2015 Survey of Clinical Practice Patterns in the Management of Thyroid Nodules.
    J Clin Endocrinol Metab. 2016 Mar 25:jc20161155.
    PubMed     Abstract available


  197. LAZAR L, Lebenthal Y, Segal K, Steinmetz A, et al
    Pediatric thyroid cancer: postoperative classifications and response-to-initial-therapy as prognostic factors.
    J Clin Endocrinol Metab. 2016 Mar 1:jc20153960.
    PubMed     Abstract available


    February 2016
  198. AHN D, Ho Sohn J, Han Jeon J
    Hypothyroidism following hemithyroidectomy: incidence, risk factors, and clinical characteristics.
    J Clin Endocrinol Metab. 2016 Feb 22:jc20153997.
    PubMed     Abstract available


  199. BIKAS A, Schneider M, Desale S, Atkins F, et al
    Effects of Dosimetrically-Guided I-131 Therapy on Hematopoiesis in Patients with Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Feb 22:jc20153544.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: